Healthy volunteers.
Conditions
Interventions
Intervention 1: Intervention group 1: In this group, volunteers are given a single oral dose of the Trentine 250 mg tablets manufactured by Daroo Darman Arang Pharmaceutical Company. In each period, 1
Sponsors
Arang Daroo Darman Company
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Having general health (liver, heart, and kidneys) Having a body mass index (18-28) Informed consent will be obtained. The age of the volunteers will be in the range if (18-60 years). No history of allergy to trientine
Exclusion criteria
Exclusion criteria: History of allergic or adverse reaction to Trientine or any similar product Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg Individuals who have donated whole blood during the last 2 months from the study Individuals who have donated blood components within 2 weeks before taking the first dose of the drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Concentration. Timepoint: 13 sampling times included pre-dose (time 0) and at the following hours post-dose: 0.5,1,1,5, 2, 3, 4, 6, 8, 12, 24, 48, 72 Hours. Method of measurement: Liquid chromatography-tandem mass spectrometry (LC-MS/MS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Ghanbarzadeh
Tabriz Univesity of Medical Science
Outcome results
None listed